Key facts
- Tafalgie Therapeutics’s last known valuation is $155.8M (Sep 2025).
- It has raised $32.0M; the latest was Later Stage VC ($14.0M) in Sep 2025.
- Notable investors include Bpifrance, European Innovation Council, Aix-Marseille University, European Innovation Council (Belgium), Incubateur Impulse — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Tafalgie Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Tafalgie Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tafalgie Therapeutics
Operator of a biopharmaceutical research company intended to develop neuropathic and inflammatory pain drugs. The company specializes in the development of next-generation pain-relieving peptides without the disabling adverse effects of opioids, enabling patients to get quick chronic pain relief from migraine, muscle pain, and neuropathies.
- Sector
- Healthcare
- HQ
- Marseille, France
- Founded
- 2020
- Employees
- 21
- Website
- tafalgie.fr/
- Ownership
- Privately Held (backing)
Tafalgie Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tafalgie Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tafalgie Therapeutics in its N-PORT filings yet. We sweep new filings monthly.